The Role of Intravenous Immunoglobulin Preparations in the Treatment of Systemic Sclerosis PDF Print E-mail
Saturday, 16 June 2012 03:43
Marta Baleva and Krasimir Nikolov
Received 12 June 2011; Revised 28 August 2011; Accepted 28 August 2011

Scleroderma is progressive autoimmune disease associated with severe disability. The major underlying pathological process in Scleroderma is progressive development of fibrous tissue and obliteration of the microvasculature. Currently, there are no medical products for the treatment of Scleroderma that provide both sufficient immunosuppression and low-risk side safety profile with negligible side effects.

There are a large number of experimental data showing that intravenous immunoglobulin (IVIG) has multiple clinical and morphological effects. On the other hand, some authors report good effect of intravenous immune globulins in patients with Scleroderma. The less frequent side effects of IVIG in doses below or equal to 2 g/kg/month divided in 5 consecutive days make IVIG a promising treatment of choice in Scleroderma.

Continue reading the full review article, by downloading it from the link provided below.

 
More articles :

» Optical Coherence Tomography: The first Quantitative Imaging Biomarker for Scleroderma

Using the , manufactured in the UK by Michelson Diagnostics Ltd, scientists at the Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds have developed the first quantitative imaging biomarker for skin involvement in . Scleroderma...

» What Is Scleroderma?

DefinitionDerived from the Greek words “sklerosis,” meaning hardness, and “derma,” meaning skin, Scleroderma literally means hard skin. Although it is often referred to as if it were a single disease, Scleroderma is really a symptom of a...

» Study Reveals New Genetic Link To Scleroderma

An international research consortium including scientists from T (UTHealth) has identified a new genetic link to the systemic form of . Researchers believe a thorough understanding of the genetic nature of the disease is crucial to developing a...

» Scleroderma Study Identifies Roadblocks To Employment

In the United States, the work disability rate for people with , also known as systemic sclerosis, is two to three times that of people with some other rheumatic conditions, according to research data from investigators at The (UTHealth) Medical...

» Natural Alternatives for Dealing With Scleroderma

In a recent article, it was noted that conventional medicine attempts to treat the symptoms of with immunosuppressant drugs, NSAIDS and , but has no cure and little advice for prevention. It was noted however, that the world of natural healing has...

» June Is Scleroderma Awareness Month!

The month of June is Scleroderma Awareness Month around the world, and would like to encourage each and everyone of you, to become advocates by raising awareness and educating others about this often progressive, autoimmune connective tissue disease...